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Abstract
We report the fi rst published case of etravirine induced hypersensitivity reaction leading to fulminant hepatic 
failure in a 49-year-old female patient with Human Immunodefi ciency Virus. She presented with a life threatening 
rash and end stage organ damage requiring intensive care unit supportive care. Liver biopsy supported the diagnosis 
of drug-induced hypersensitivity. The patient recovered after withdrawal of etravirine and the use of systemic 
corticosteroids. The authors describe etravirine drug hypersensitivity as a clinically important reaction and that early 
recognition can improve survival. 
Keywords: Human immunodefi ciency virus; Hepatitis; Antiretrovi-
ral therapy; Drug hypersensitivity; Etravirine 
Introduction
     Etravirine is a second generation non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) used in treatment-experienced patients or pa-
tients with drug resistant Human Immunodefi ciency Virus (HIV). In 
a pooled analysis of phase III trials, etravirine demonstrated a favor-
able safety profi le compared with control with the exception of rash re-
ported more frequently with etravirine than placebo, 21% versus 12%, 
respectively [1,2].
Despite etravirine’s safety profi le in clinical trials, several post-mar-
keting reports of severe skin reactions which include hypersensitivity 
reactions resulting in hepatic failure have recently been identifi ed. As 
a result, Janssen Th erapeutics, formerly Tibotec Pharmaceuticals, and 
the Food and Drug Administration issued a letter informing healthcare 
professionals of such fi ndings [3,4]. To date, we report the fi rst case of a 
life threatening hypersensitivity reaction to etravirine resulting in rash 
and fulminant hepatic failure.
Observation
A 49-year-old African American woman with HIV and resolved 
hepatitis B had been taking highly active antiretroviral therapy 
(HAART) for over 10 years. She had adverse reactions to indinavir, 
nelfi navir, abacavir, efavirenz, nevirapine and tenofovir and her anti-
retroviral therapy (ART) had been limited to didanosine and stavu-
dine. With the approval of etravirine and raltegravir, the patient’s ART 
was changed to etravirine 200 mg, raltegravir 400 mg, and lopinavir/
ritonavir 400 mg/100 mg each given twice daily. Her baseline CD4 
count was 216 cells/mL and her viral load was 902 copies/mL prior 
to the initiation of this regimen. Liver function tests, complete blood 
counts, and electrolytes were within normal limits. She was not on any 
other medications or herbal supplements. She also denied alcohol use. 
Th ree weeks aft er beginning her new HAART, she developed a diff use 
maculopapular rash. Despite discontinuation of the antiretroviral ther-
apy, her rash progressed with involvement of her entire body and she 
developed fever, jaundice, emesis, and diarrhea. Physical examination 
revealed a febrile, encephalopathic and severely jaundiced patient with 
a diff use maculopapular rash on the face, chest, abdomen, and extremi-
ties sparing her mucous membranes, with early signs of desquamation. 
She had hepatomegaly and right upper quadrant tenderness. 
Laboratory studies on admission revealed a white blood cell count 
of 13.3 x 103/μL with 10% eosinophils (normal, 0-5%) and absolute 
eosinophils 1.3 x 103 cells/μL (normal, 0-0.65 x 103 cells/μL). Liver 
enzyme peak values were aspartate transaminase 2364 IU/L, alanine 
transaminase 1174 IU/L, total bilirubin 19.4 mg/dL, and INR 3.05 on 
her day of hospitalization. Acute hepatitis panel for Hepatitis A, B, and 
C were negative. Hepatitis B Viral DNA PCR was undetectable and 
Hepatitis C RNA PCR was less than 50 IU/mL. HIV-1 RNA quantita-
tive PCR was less than 48 copies/mL. A urine toxicology screen was 
negative for acetaminophen. Except for hepatomegaly, an abdominal 
ultrasound was unremarkable for liver lesions and showed a patent he-
patic vasculature. A transjugular liver biopsy showed confl uent multi-
acinar hepatic necrosis with portal mixed infl ammatory infi ltrates in-
cluding eosinophils, activated lymphocytes and plasma cells suggestive 
of a drug induced etiology (Figure 1). 
She was considered for liver transplant due to fulminant and 
worsening hepatic failure. She was managed in the intensive care unit 
with aggressive fl uid-electrolyte management, empiric antibiotics, ri-
faximin and lactulose. However she only improved aft er intravenous 
methylprednisolone was administered. Aft er which, she made a slow 
but steady recovery. Because of her signifi cant improvement, she did 
not need a liver transplant and was discharged home aft er fi ft een days 
of hospitalization. Her liver function tests normalized six weeks aft er 
etravirine was discontinued.
Discussion
Our case report underscores the importance of recognizing drug 
induced hypersensitivity syndrome (DHS) from etravirine use. DHS, 
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also known as drug rash with eosinophilia and systemic symptoms, is 
characterized by exfoliative dermatitis, fever and potentially life threat-
ening end organ damage [5,6]. Severe DHS has been reported in less 
than 2% of all HIV-infected individuals treated with NNRTIs and most 
commonly described with nevirapine use [7,8,9]. In clinical practice, 
severe cutaneous reactions appear to be less common with efavirenz 
than with nevirapine. The incidence of DHS in efavirenz is 0.14% in all 
studies [10]. Rilpivirine licensure was recently approved in May, 2011. 
To date, no cases of rilpivirine associated DHS have been reported.
The primary cause of mortality in DHS is fulminant hepatic failure, 
occurring between 1 and 6 weeks after the initiation of drug therapy 
and often necessitates liver transplant [11,12]. Our patient presented 
with an exfoliative rash, eosinophilia, and hepatic failure approxi-
mately 3 weeks after initiation of etravirine. Histopathologic findings 
on liver biopsy associated with DHS include necrosis, cholestasis, and 
eosinophilic infiltration, as was seen in our case [5]. 
DHS caused by nevirapine has been well documented in the litera-
ture. Historically, this adverse reaction has been associated in women 
with CD4 counts greater than 250 cells/mm3 and men with CD4 counts 
greater than 400 cells/mm3. Liver biopsy results in these patients have 
found eosinophilic and lymphocytic infiltration consistent with an 
immune mediated mechanism and frequently necrosis. Based on the 
case reports of nevirapine induced liver injury, the median onset of 
symptoms is typically 14 days and the median time to improvement 
is 21.5 days [8,9,12]. Our case is similar to DHS caused by nevirapine 
in several ways. First, our patient presented with severe rash and ful-
minant hepatic failure 21 days into initiation of her etravirine based 
regimen. Second, her liver biopsy was similar to the pattern seen with 
nevirapine hepatotoxicity. Finally, her liver function tests normalized 
within 6 weeks of etravirine withdrawal, which is similar to the time-
frame of resolution of nevirapine induced hepatitis. Our patient previ-
ously had a rash to both the NNRTIs, efavirenz and nevirapine without 
hepatoxicity. It remains to be elucidated if adverse reactions from prior 
exposure to NNRTIs poses a risk factor for DHS and should not be 
overlooked. 
The Roussel Uclaf Causality Assessment Method of the Council for 
International Organizations of Medical Sciences (RUCAM/CIOMS) is 
one of the most widely used scales for establishing a causal relationship 
between the offending drug and liver damage. Application to our case 
showed a causality of this adverse drug reaction using the RUCAM/
CIOMS scale of seven or “probable” adverse reaction [13,14].
Our patient was also on raltegravir and lopinavir/ritonavir. Ralte-
gravir is generally a well-tolerated HIV-1 integrase inhibitor. A review 
of the current literature through PubMED shows limited data on the 
toxicity and side effects of this medication. A common adverse effect 
with raltegravir use is elevated alkaline phosphatase levels, which can 
range between 2.6 to five times the upper limit of normal [15,16]. El-
evated creatinine phosphokinase levels in association with myopathy 
and rhabdomyolysis have also been reported [17]. In November 2011, 
the FDA added rash and hypersensitivity reaction to the warning and 
precaution section of raltegravir [16]. However our patient was re-
challenged with raltegravir after hospital discharge and has been on 
raltegravir for over one year without any adverse reaction. Lopinavir/
ritonavir combination has been associated with mild to moderate he-
patic impairment and this is usually limited to patients with Hepatitis 
C viremia and baseline hepatic insufficiency [18]. Lopinavir/ritonavir 
has rarely been associated with drug hypersensitivity reaction. We ex-
cluded lopinavir/ritonavir as the offending drug in our patient as she 
tolerated it in the past without any rash or liver abnormalities. 
Our case was one of first post-licensure reports of etravirine in-
duced hypersensitivity reaction with hepatic failure. A request to Jans-
sen Therapeutics for details on the additional reported hypersensitivity 
cases presented in the etravirine investigator’s brochure was declined 
at this time. We searched medline through PubMed using the words 
etravirine, hypersensitivity, Stevens Johnson syndrome and toxic epi-
dermal necrolysis to look for cases of hypersensitivity reaction and end 
organ failure. To the best of our knowledge, this is the first published 
case report of etravirine induced drug hypersensitivity reaction. If not 
recognized with prompt removal of the offending agent, DHS can lead 
to significant morbidity and mortality. Early administration of intrave-
nous corticosteroids may be beneficial and may improve patient out-
come [11,19]. 
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